Tradestie Institutional Equity Comparison Engine

ENTX vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ENTX Overall Edge

ENTX Captures Institutional Edge (2โ€“0 Pillars ยท 5โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ENTX N/M vs CDT N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner ENTX
1Y +24.7% vs -86.8% ยท 52W Pos 73% vs 2%
Options & Structure Winner ENTX
CONSOLIDATION (33rd %ile IV) vs BREAKDOWN (N/A IV)
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
1M Return +9.44%
1Y Return +24.72%
Forward P/E N/M
Unified AI Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENTX +24.72% CDT -86.78% Spread: +111.5 pp (ENTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ENTX TTM Op. Margin: 0.0% CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTX vs CDT. Trailing 12-month operating profitability (ENTX 0.0% vs CDT 0.0%) and valuation multiples (ENTX N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENTX (5) vs CDT (1)
Institutional Metric ENTX CDT Criterion Row Winner
Market Capitalization Scale $571.2M $507,528 Larger Scale ENTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +0.0% Higher Growth CDT
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -20.3% -69.7% Higher ROE ENTX
52-Week Range Position Momentum 73% ($1โ€“$4) 2% ($0โ€“$11) Stronger Trend ENTX
Beta / 30D Volatility Risk Regime 0.92ฮฒ ยท 53% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk ENTX
Unified Institutional Score Composite Signal 47.5 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite ENTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENTX vs CDT Buy Guide
ENTX CONSOLIDATION
83d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 33rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENTX nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.